Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
11 resultat
Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates to a nitrogen-containing bicyclic compound or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising it as active ingredient.
More specifically, the present invention relates to (1) a compound of formula (I)
##STR00002##
Substituted benzopyrans as selective estrogen receptor-beta agonists
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
The present invention relates to novel benzopyran ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon
Piperidine derivative compounds and drugs containing the compounds as the active ingredient
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates to a piperidine derivative.
More specifically, the present invention relates to (1) a piperidine derivative of formula (I)
##STR00002## (2) a method for the preparation thereof, (3) a composition comprising it as an active ingredient, (4) a compound of
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is a frequently inherited kidney disorder with a gene frequency of 1 in 500 to 1,000 births affecting nearly 600,000 Americans and as many as 12 million people worldwide. This potentially lethal genetic disease is characterized by the
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is a frequently inherited kidney disorder with a gene frequency of 1 in 500 to 1,000 births affecting nearly 600,000 Americans and as many as 12 million people worldwide. This potentially lethal genetic disease is characterized by the
Methods of screening for compounds which bind G protein-coupled receptors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the 35 U.S.C. .sctn.371 national stage of PCT application PCT/JP2005/007354, filed Apr. 11, 2005, which claims priority to Japanese patent application No. 116725/2004, filed Apr. 12, 2004. The contents of these applications are incorporated
Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to compounds which modulate one or more of ERalpha/beta and GPR30 receptors, to pharmaceutical compositions based upon those compounds and to methods of treating disease states and conditions mediated through these receptors and related methods
Compounds for binding to ER.alpha./.beta. and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to compounds which modulate one or more of ERalpha/beta and GPR30 receptors, to pharmaceutical compositions based upon those compounds and to methods of treating disease states and conditions mediated through these receptors and related methods
Substituted tetralins as selective estrogen receptor-.beta. agonists
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
The present invention relates to novel tetralin ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon
Piperidine derivatives and agent comprising the derivative as active ingredient
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates to piperidine derivatives.
More specifically, the present invention relates to
(1) piperidine derivatives represented by formula (I):
##STR00002## (wherein all symbols have the same meanings as described below), or nontoxic salts thereof, (2) a process
Piperidine derivatives and agent comprising the derivative as active ingredient
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates to piperidine derivatives.
More specifically, the present invention relates to (1) piperidine derivatives represented by formula (I):
##STR00002## (wherein all symbols have the same meanings as described below), or nontoxic salts thereof, (2) a process
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
